A5013185325- Renal cell carcinoma treatment
- Renal and related cancers
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Cancer Genomics and Diagnostics
- Prostate Cancer Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Pediatric Urology and Nephrology Studies
- Cancer Immunotherapy and Biomarkers
- Renal and Vascular Pathologies
- Organ Donation and Transplantation
- Multiple and Secondary Primary Cancers
- Urinary and Genital Oncology Studies
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
- Neuroblastoma Research and Treatments
- Urological Disorders and Treatments
- MRI in cancer diagnosis
- Cancer, Hypoxia, and Metabolism
- Pancreatic and Hepatic Oncology Research
- Renal Transplantation Outcomes and Treatments
- Tuberous Sclerosis Complex Research
- Genetic and Kidney Cyst Diseases
- Cancer Diagnosis and Treatment
- Cancer, Stress, Anesthesia, and Immune Response
St. Joseph’s Healthcare Hamilton
2015-2025
McMaster University
2016-2025
People’s University
2011-2025
Juravinski Cancer Centre
2015-2024
St. Joseph's Hospital
2012-2023
Sheffield Children's Hospital
2023
Flushing Hospital Medical Center
2023
University of Mississippi Medical Center
2022
University of Lagos
2022
University of Michigan
2022
Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target rapamycin kinase, may benefit patients with this disease.In multicenter, phase 3 trial, we randomly assigned 626 previously untreated, poor-prognosis to receive 25 mg intravenous temsirolimus weekly, million U interferon (with an increase 18 U) subcutaneously three times or combination therapy 15 weekly plus 6 weekly. The...
Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared that sunitinib is unclear.
You have accessJournal of UrologyAdult Urology1 Aug 2019Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline Jennifer Anger, Una Lee, A. Lenore Ackerman, Roger Chou, Bilal Chughtai, J. Quentin Clemens, Duane Hickling, Anil Kapoor, Kimberly S. Kenton, Melissa R. Kaufman, Mary Ann Rondanina, Stapleton, Lynn Stothers, and Toby C. Chai AngerJennifer Anger American Urological Association Education Research, Inc., Linthicum, Maryland , LeeUna Lee AckermanA. Ackerman...
LBA4 Background: Temsirolimus (TEMSR, CCI-779) is a specific inhibitor of mTOR, signaling protein that regulates cell growth and angiogenesis. In single-agent, phase 2 study, TEMSR administration to heavily pretreated patients (pts, n = 111) with adv RCC resulted in median overall survival (OS) 15.0 mos (Atkins et al, J Clin Oncol 2004). Retrospectively, 49 pts were categorized poor-risk group (Motzer 2002). The TEMSR-treated this had 1.7-fold longer OS than the first-line, IFN-treated,...
OBJECTIVE To evaluate the usefulness of urinary calculi attenuation values from non‐contrast computed tomography (NCCT) in predicting outcome treatment by extracorporeal shock wave lithotripsy (ESWL). PATIENTS AND METHODS We evaluated 112 patients with solitary renal and upper ureteric 0.5–2 cm undergoing ESWL. All had NCCT at 120 kV 240 mA on a spiral CT scanner. During each ESWL session 3000 waves were given to maximum 3.0 kV. A final X‐ray kidney, ureters bladder was taken 12 weeks after...
Recurrent uncomplicated urinary tract infection (UTI) is a common presentation to urologists and family doctors. Survey data suggest that 1 in 3 women will have had diagnosed treated UTI by age 24 more than half be affected their lifetime.1 In 6-month study of college-aged women, 27% these UTIs were found recur once 3% second time.2 The following topics are reviewed this guideline. We also include summary recommendations (Text box 1). Text 1. Summary...
With advances in modern imaging technology, the presentation of an incidentally found adrenal mass (or incidentaloma) has become increasingly common management scenario for endocrinologists and urologists. The prevalence incidentalomas (AI) been reported as high 8% autopsy series 4% radiologic series.1,2 As improved techniques available frequency abdominal increases, is expected to continue escalating, approaching series. Also concerning evidence supporting increased with age, risk finding...
Girentuximab is a chimeric monoclonal antibody that binds carbonic anhydrase IX, cell surface glycoprotein ubiquitously expressed in clear renal carcinoma (ccRCC). Its safety and activity phase 2 studies prompted investigation into its use as adjuvant monotherapy participants with high-risk ccRCC.To evaluate the efficacy of girentuximab on disease-free survival (DFS) overall (OS) patients localized completely resected ccRCC.The ARISER trial (Adjuvant Rencarex Immunotherapy Phase 3 Trial to...
PTEN is a potent tumor-suppressor protein. Aggressive and metastatic prostate cancer (PC) associated with reduction or loss of expression. often occurs without gene mutations, its downregulation not fully understood. Herein, we show that incorporated in the cargo exosomes derived from cells. detected normal, noncancerous We found can be transferred to other cells through exosomes. In have complete expression, competent confer tumor-suppression activity acceptor PC patients, circulate their...
Agents that have shown improvements in survival mCRPC now include abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223. Bone supportive agents palliative radiation continue to play an important role the overall management of mCRPC. Given complexity, variety importance optimizing use these agents, a multidisciplinary team approach is highly recommended.
4502 Background: In the phase 3 CLEAR trial, L+P showed clinically meaningful and statistically significant benefits in PFS (primary endpoint) OS, improved ORR compared with S 1L aRCC (Motzer NEJM 2021). Here, we report 4-yr follow-up results from final prespecified OS analysis of (data cutoff: 31 Jul 2022). Methods: Treatment-naïve pts (n=1069) who had a clear-cell component were randomized (1:1:1) to receive: L 20 mg PO QD + P 200 IV Q3W; or 18 everolimus 5 QD; 50 (4 wks on/2 off)....
The identification of early inflammatory events after transplant in solid tissue organ grafts that may direct T cell recruitment and promote acute allograft rejection remain largely unknown. To better understand temporal aspects vascularized grafts, we tested the intragraft expression four different chemokines heterotopically transplanted A/J (H-2(a)) syngeneic heart C57BL/6 (H-2(b)) recipient mice from 1.5 to 48 h transplant. Similar patterns equivalent levels chemokine were observed both...
Chromatin structure is influenced by histone modification, and this may help direct chromatin behavior to facilitate transcription, DNA replication, repair. condensation fragmentation are the classic nuclear features but remain poorly characterized. It highly probable that nucleosomal must be altered allow these become apparent, data support construct lacking. We report here in response apoptotic signals from a death receptor (CD95 tumor necrosis factor-α) or mitochondrial (staurosporine)...